

ASX RELEASE

Appendix 3Y – Ralph Highnam

Wellington, NZ, 22 November 2019: [Volpara Health Technologies](#) (“Volpara”; ASX: VHT), an SaaS medical technology company whose AI imaging algorithms assist the early detection of breast cancer, has today released an ASX Appendix 3Y Change of Director’s Interest Notice for Ralph Highnam, CEO and Executive Director, giving notice that he has undertaken a personal restructure of his share portfolio and transferred his VHT shareholding into a family trust of which he is a beneficiary. No shares have been sold.

ENDS

For further information, please contact:

Ralph Highnam, CEO
Volpara Health Technologies
ralph.highnam@volparasolutions.com
t: +64 21 149 0541

Trevor Chappell
WE Communications
tchappell@we-worldwide.com
t: +61 3 9866 1215

ABOUT VOLPARA HEALTH TECHNOLOGIES LIMITED (ASX: VHT)

VHT is a MedTech SaaS company founded in 2009 on research originally conducted at Oxford University. VHT’s clinical applications for screening clinics provide feedback on breast density, compression, dose, and quality, while its enterprise-wide practice software management helps with productivity, compliance, reimbursement, and patient tracking.

VHT’s technology and services have been used by customers and/or research projects in 38 countries and are supported by numerous patents, trademarks, and regulatory clearances, including FDA clearance and CE marking. Since its listing on the ASX in April 2016, VHT has raised A\$95 million, including A\$55 million in June 2019. VHT is based in Wellington, New Zealand.

At the end of June 2019, VHT acquired MRS, a company based in Seattle, WA. MRS provides mammography reporting systems to over 1,600 breast clinics and hospitals, and to VHT a much stronger US presence, experienced local headquarters, and accelerated sales through cross-selling opportunities.

For more information, visit www.volparasolutions.com.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Volpara Health Technologies Limited
ABN	609 946 867

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Ralph Highnam
Date of last notice	12 September 2019

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect for shares Direct for options
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Highnam Share Trust Ralph Highnam has undertaken a personal restructure of his shareholding and transferred his current shareholding in VHT to the Highnam Share Trust, under which he is a beneficiary.
Date of change	22 November 2019
No. of securities held prior to change	Ralph Highnam 16,190,485 – Fully Paid Ordinary Shares 600,000 – Options over Ordinary Shares
Class	Ordinary Shares and options over ordinary shares
Number acquired	Nil (personal restructure of shares from Ralph Highnam to Highnam Share Trust)
Number disposed	Nil (personal restructure of shares from Ralph Highnam to Highnam Share Trust)
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	N/A

+ See chapter 19 for defined terms.

Appendix 3Y Change of Director's Interest Notice

No. of securities held after change	Highnam Share Trust - 16,190,485 - Ordinary Shares Ralph Highnam - 600,000 Options over Ordinary Shares
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Personal restructure of shareholding

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.